BioInvent: New Paper in Cell Highlights the Potential Role of TB-403 (anti-PlGF) in the Treatment of Medulloblastoma, a Pediatric Brain Tumor

LUND, Sweden & LEUVEN, Belgium--()--Regulatory News:

BioInvent International AB (STO:BINV) and co-development partner ThromboGenics NV (Euronext Brussels: THR), announce today the publication of a paper in the prestigious journal Cell, highlighting the potential of TB-403 to improve the treatment of medulloblastoma, the most common brain tumor in children.

The Cell publication highlights for the first time a new mechanism of action, showing that PlGF plays a vital role in the brain and that its expression is required for the growth and spread of medulloblastoma.

The novel positive findings in this paper provide evidence that could warrant further development of TB-403 as one of the first targeted therapies to treat this childhood cancer. TB-403 is a monoclonal antibody against placental growth factor (PlGF). PIGF is a naturally occurring protein that belongs to the family of vascular endothelial growth factors (VEGF) that promote the formation of blood vessels.

TB-403 was in-licensed by ThromboGenics from the Flanders Institute for Biotechnology (VIB), where the therapeutic potential of anti-PlGF agents to treat cancer was first developed by Prof. Peter Carmeliet at the University of Leuven, Belgium.

This Cell paper is reporting the findings of new pre-clinical research performed at the Massachusetts General Hospital in Harvard (Boston), in collaboration with the team of Prof Peter Carmeliet.

With an emerging ophthalmologic franchise, Thrombogenics is also evaluating the role of TB-403 for ophthalmic indications.

To the editors:

About BioInvent

BioInvent International AB, listed on the NASDAQ OMX Stockholm (BINV), is a research-based pharmaceutical company focused on discovery and development of innovative antibody-based drugs against cancer. The Company's pipeline currently includes three product candidates for the treatment of cancer.

The company's competitive position is underpinned by n-CoDeR®, a proprietary antibody development platform. The scope and strength of this platform is also used to develop antibody-based drugs in collaboration with partners who finance the development of the new drug, and provide BioInvent the right to milestone payments and royalties on sales. These partners include Bayer HealthCare, Daiichi Sankyo, Mitsubishi Tanabe and Servier. More information is available at www.bioinvent.com.

About ThromboGenics

ThromboGenics is an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines. The Company’s lead product, JETREA® (ocriplasmin), has been approved by the US FDA for the treatment of symptomatic VMA and was launched in January 2013.

In March 2012, ThromboGenics signed a strategic partnership with Alcon (Novartis) for the commercialization of JETREA® outside the United States. Under this agreement, ThromboGenics could receive up to a total of €375 million in up-front and milestone payments. It will receive significant royalties from Alcon’s net sales of JETREA®. ThromboGenics and Alcon intend to share the costs equally of developing JETREA® for a number of new vitreoretinal indications.

The JETREA European Marketing Authorisation Application is currently under review by the European Medicines Agency. Following the positive CHMP recommendation, a final decision by the European Commission on European approval is expected in the first half of 2013.

ThromboGenics is also further exploring anti-PIGF (Placental Growth Factor), formerly referred to as TB-403, for the treatment of ophthalmic indications.

ThromboGenics is headquartered in Leuven, Belgium, and has-offices in Iselin, NJ (US) and Dublin, Ireland. The Company is listed on the NYSE Euronext Brussels exchange under the symbol THR. More information is available at www.thrombogenics.com.

Legal disclaimer

The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same was as research and development work in the

biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.

Information disclosed in this press release is provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 6.00 p.m. CET, on 28 February 2013.

This information was brought to you by Cision http://news.cision.com

Contacts

BioInvent International AB
D.Sc., Cristina Glad
President & CEO
+46 (0)46 286 85 51
+46 (0)708 16 85 70
cristina.glad@bioinvent.com
www.bioinvent.com
or
The Trout Group
Christine Yang
Vice President
+1 646 378 2929
cyang@troutgroup.com
or
ThromboGenics
Wouter Piepers
Global Head of Corporate Communications
+32 16 75 13 10 / +32 478 33 56 32
wouter.piepers@thrombogenics.com
or
Dr. Patrik De Haes, CEO
+32 16 75 13 10
Patrik.dehaes@thrombogenics.com
or
Chris Buyse, CFO
+32 16 75 13 10
Chris.buyse@thrombogenics.com
or
Citigate Dewe Rogerson
David Dible/ Nina Enegren/ Sita Shah
+44 20 7638 9571
sita.shah@citigatedr.co.uk
or
The Trout Group (US investor relations)
Todd James/ Simon Harnest
tjames@troutgroup.com

Sharing

Contacts

BioInvent International AB
D.Sc., Cristina Glad
President & CEO
+46 (0)46 286 85 51
+46 (0)708 16 85 70
cristina.glad@bioinvent.com
www.bioinvent.com
or
The Trout Group
Christine Yang
Vice President
+1 646 378 2929
cyang@troutgroup.com
or
ThromboGenics
Wouter Piepers
Global Head of Corporate Communications
+32 16 75 13 10 / +32 478 33 56 32
wouter.piepers@thrombogenics.com
or
Dr. Patrik De Haes, CEO
+32 16 75 13 10
Patrik.dehaes@thrombogenics.com
or
Chris Buyse, CFO
+32 16 75 13 10
Chris.buyse@thrombogenics.com
or
Citigate Dewe Rogerson
David Dible/ Nina Enegren/ Sita Shah
+44 20 7638 9571
sita.shah@citigatedr.co.uk
or
The Trout Group (US investor relations)
Todd James/ Simon Harnest
tjames@troutgroup.com